Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BGMA Warns That Policy Vacuum Risks UK Becoming ‘Supply Backwater’

As General Election Looms, Association Lays Out A ‘Manifesto‘ With Potential Solutions

Executive Summary

With a UK general election looming, local generics and biosimilars industry association the BGMA has warned that the country will be “deprioritized as a supply market” without a more focused and supportive policy environment for the off-patent sector.

You may also be interested in...



UK Industry Urges Labour To Go Further With Life Sciences Plan

A life sciences plan unveiled by the UK’s Labour party – which polls indicate is likely to take power after the country’s imminent general election – could “go further in considering the role of off-patent medicines,” the BGMA believes.

Boehringer’s Slashed Cyltezo Salesforce Reflects Struggles For US Humira Biosimilars

Boehringer Ingelheim’s decision not only reflects the company’s difficulties in gaining traction for the first interchangeable version of adalimumab, but also the wider problems for Humira biosimilars in the US.

Boehringer’s Slashed Cyltezo Salesforce Reflects Struggles For US Humira Biosimilars

Boehringer Ingelheim’s decision to cut sales staff for its Cyltezo US biosimilar rival to Humira not only reflects the company’s difficulties in gaining traction for the first interchangeable version of adalimumab, but also the struggles for Humira biosimilars more widely.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153390

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel